Jivolar

Active Ingredient:: Metformin Hydrochloride, Sitagliptin
Origin:: EU

Jivolar (Metformin Hydrochloride, Sitagliptin)

Q: What is Jivolar used for?

Jivolar is prescribed for the management of type 2 diabetes mellitus in adult patients. It combines metformin, which improves insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to help lower elevated blood glucose levels as part of a comprehensive treatment plan.

Q: How does Metformin Hydrochloride and Sitagliptin work?

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, raising endogenous incretin levels. The higher incretin concentrations stimulate glucose‑dependent insulin release and suppress glucagon, together improving overall glycaemic control.

Q: What is the usual dose of Jivolar?

The specific dose of Jivolar is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the dose regimen provided by their prescriber and not adjust it without medical advice.

Q: Is Jivolar safe during pregnancy or breastfeeding?

Safety of Jivolar in pregnancy and lactation has not been established. Clinicians must weigh the potential benefits against possible risks to the fetus or infant, and consider alternative treatments when appropriate. Pregnant or nursing patients should discuss therapy options with their healthcare provider.

Q: How do I order Jivolar from GNH India?

To order Jivolar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Q: How does Jivolar compare with other antidiabetic options?

Jivolar combines two established mechanisms—metformin’s insulin‑sensitising effect and sitagliptin’s DPP‑4 inhibition—offering a single‑tablet regimen. Compared with metformin monotherapy, it provides additional glucose‑lowering capacity, and versus separate DPP‑4 inhibitors, it reduces pill burden. It is generally considered when glycaemic control is not achieved with metformin alone.

Q: What are the storage and handling requirements for Jivolar?

Jivolar tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Q: How is Jivolar administered?

Jivolar is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

Q: What are the most serious risks associated with Jivolar?

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycaemia, especially when combined with insulin or sulfonylureas. Pancreatitis and allergic reactions are also rare but serious adverse events that require immediate medical attention.

Q: Who should not use Jivolar?

Jivolar is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jivolar, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to lower elevated blood glucose levels when used in combination with diet and exercise.

GNH India supplies Jivolar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines for chronic disease management and supporting patient care programs.

Manufacturer / TM Owner

Medochemie Ltd.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jivolar combines metformin and sitagliptin to address hyperglycaemia in type 2 diabetes mellitus.

Type 2 diabetes mellitus (initial therapy): lowers fasting and post‑prandial glucose levels as part of a comprehensive treatment plan.
Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when metformin alone is insufficient.
Type 2 diabetes mellitus (metformin intolerance): provides glucose reduction via DPP‑4 inhibition for patients who cannot tolerate metformin.

How It Works

Metformin reduces hepatic gluconeogenesis and improves peripheral insulin sensitivity, while sitagliptin selectively inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4). This inhibition raises endogenous incretin concentrations, which augment glucose‑dependent insulin secretion and suppress glucagon release, together producing better overall glycaemic control in type 2 diabetes.

Side Effects

Jivolar may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
Headache: mild to moderate intensity.
Mild hypoglycaemia: especially when combined with insulin or sulfonylureas.
Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects

Lactic acidosis: a rare but potentially fatal metabolic complication.
Severe hypoglycaemia: prolonged low blood glucose requiring medical intervention.
Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
Allergic reactions: rash, itching, or angioedema.
Hepatic dysfunction: abnormal liver enzyme elevations.
Renal impairment: worsening kidney function in susceptible individuals.

Precautions & Warnings

Before prescribing Jivolar, clinicians should evaluate patient-specific risk factors and monitor relevant parameters.

Renal function: assess eGFR before initiating and periodically monitor kidney performance.
Hepatic function: use with caution in patients with existing liver disease.
Lactic acidosis risk: avoid in conditions predisposing to hypoxia such as severe heart failure or respiratory compromise.
Pregnancy and lactation: safety not established; weigh potential benefits against risks.
Drug interactions: review concomitant medications for possible pharmacodynamic or pharmacokinetic conflicts.
Store at ambient temperature: keep below 25 °C, retain in the original packaging, and protect from moisture.

Avoid Interactions

Jivolar can interact with several medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min/1.73 m²): contraindicated due to lactic acidosis risk.
Co‑administration with other DPP‑4 inhibitors: duplicate therapy should be avoided.
Potent CYP2C8 inhibitors: may increase metformin plasma concentrations.
Combined use with insulin or sulfonylureas: heightened risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

Alcohol intake: may potentiate metformin‑associated lactic acidosis.
Iodinated contrast media: temporary discontinuation of metformin is recommended.
Beta‑blockers: can mask symptoms of hypoglycaemia, requiring closer glucose monitoring.

Frequently Asked Questions

Jivolar is prescribed for the management of type 2 diabetes mellitus in adult patients. It combines metformin, which improves insulin sensitivity, with sitagliptin, a DPP‑4 inhibitor that enhances insulin secretion, to help lower elevated blood glucose levels as part of a comprehensive treatment plan.

Metformin Hydrochloride reduces hepatic glucose production and increases peripheral insulin sensitivity, while Sitagliptin blocks the DPP‑4 enzyme, raising endogenous incretin levels. The higher incretin concentrations stimulate glucose‑dependent insulin release and suppress glucagon, together improving overall glycaemic control.

The specific dose of Jivolar is determined by the prescribing healthcare professional based on individual patient factors such as renal function, glycaemic targets, and concomitant therapies. Patients should follow the dose regimen provided by their prescriber and not adjust it without medical advice.

Safety of Jivolar in pregnancy and lactation has not been established. Clinicians must weigh the potential benefits against possible risks to the fetus or infant, and consider alternative treatments when appropriate. Pregnant or nursing patients should discuss therapy options with their healthcare provider.

To order Jivolar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets, and will request verification of trade or institutional credentials. The team then replies with pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Jivolar combines two established mechanisms—metformin’s insulin‑sensitising effect and sitagliptin’s DPP‑4 inhibition—offering a single‑tablet regimen. Compared with metformin monotherapy, it provides additional glucose‑lowering capacity, and versus separate DPP‑4 inhibitors, it reduces pill burden. It is generally considered when glycaemic control is not achieved with metformin alone.

Jivolar tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the packaging remains tightly closed until use.

Jivolar is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious risks include lactic acidosis, a rare but potentially fatal condition linked to metformin, and severe hypoglycaemia, especially when combined with insulin or sulfonylureas. Pancreatitis and allergic reactions are also rare but serious adverse events that require immediate medical attention.

Jivolar is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to metformin, sitagliptin, or any excipients, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease or acute heart failure.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 15 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.